$18.82
-6.8%Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
KMTS • NASDAQ
| Kestra Medical Technologies, Ltd. Income Statement | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2021 | Apr 2020 |
|---|---|---|---|---|---|
REVENUE | |||||
59.8M | 27.8M | 7.6M | 0.0 | 0.0 | |
GROSS PROFIT | |||||
(35.6M) | (27.5M) | (18.3M) | (0.0) | (0.0) | |
24.2M | 362K | -10.7M | 0.0 | 0.0 | |
OPERATING INCOME | |||||
(130.6M) | (85.4M) | (69.8M) | (32.7M) | (29.3M) | |
(114.9M) | (69.9M) | (54M) | (13.9M) | (6.5M) | |
(15.7M) | (15.5M) | (15.8M) | (18.8M) | (22.8M) | |
-106.4M | -85.1M | -80.4M | -32.7M | -29.3M | |
PRE-TAX INCOME | |||||
(7.7M) | (6.2M) | (5.6M) | (1.2M) | (0.0) | |
-4.5M | -6.2M | -5.6M | -1.2M | 0.0 | |
-7.3M | -9M | -3.8M | -1.2M | 0.0 | |
-113.7M | -94.1M | -84.2M | -33.9M | -29.3M | |
NET INCOME | |||||
(135K) | (24K) | (15K) | (187K) | (148K) | |
-113.8M | -94.1M | -84.2M | -34.1M | -29.5M |
KMTS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | March 17, 2026 | January 31, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 11, 2025 | December 11, 2025 | 2025 | |
10-Q 10-Q 2025 Q4 Q4 | December 11, 2025 | October 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 04, 2025 | December 02, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 01, 2025 | December 01, 2025 | 2025 | |
S-1 S-1 N/A | December 01, 2025 | December 01, 2025 | ||
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | September 12, 2025 | July 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 11, 2025 | September 11, 2025 | 2025 |
Continue your KMTS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.